Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2021-02-05 11:42 am Sale | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | STATE STREET CORP STT | 11,056,979 6.26% | -6,896,891 (-38.41%) | View |
| 2021-01-28 5:56 pm Purchase | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | BlackRock Inc. BLK | 16,259,745 9.2% | 4,109,534 (+33.82%) | View |
| 2021-01-25 4:43 pm Purchase | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | Sarissa Capital Management LP | 8,844,000 5% | 8,844,000 (New Position) | View |
| 2020-12-10 07:14 am Purchase | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | STATE STREET CORP STT | 17,953,870 10.17% | 17,953,870 (New Position) | View |
| 2020-06-10 5:07 pm Purchase | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | CITADEL ADVISORS LLC | 8,895,435 5% | 8,895,435 (New Position) | View |
| 2020-04-17 5:30 pm Purchase | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | ADAGE CAPITAL PARTNERS GP L.L.C. | 2,500,000 1.62% | 2,500,000 (New Position) | View |
| 2020-02-14 5:14 pm Sale | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | Point72 Asset Management L.P. | 8,388,054 5.4% | -967,328 (-10.34%) | View |
| 2020-02-14 4:34 pm Sale | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | RA CAPITAL MANAGEMENT L.P. | 0 0% | -10,660,349 (Position Closed) | View |
| 2020-02-14 4:20 pm Sale | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | GREAT POINT PARTNERS LLC | 0 0% | -7,622,256 (Position Closed) | View |
| 2020-02-14 4:14 pm Purchase | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | BAKER BROS. ADVISORS LP | 15,875,125 9.99% | 703,585 (+4.64%) | View |
| 2020-02-13 1:17 pm Sale | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | JANUS HENDERSON GROUP PLC JHG | 9,408,481 8.5% | -2,894,074 (-23.52%) | View |
| 2020-02-13 12:33 pm Sale | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | Flynn James E | 6,375,143 4.14% | -535,646 (-7.75%) | View |
| 2020-02-12 11:16 am Purchase | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | VANGUARD GROUP INC | 8,121,631 5.27% | 2,249,402 (+38.31%) | View |
| 2020-02-05 11:25 am Purchase | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | BlackRock Inc. BLK | 12,150,211 7.9% | 3,300,784 (+37.30%) | View |
| 2020-01-22 5:01 pm Purchase | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | INTEGRATED CORE STRATEGIES (US) LLC | 9,975,477 6.5% | 3,781,473 (+61.05%) | View |
| 2019-11-19 4:42 pm Purchase | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | Point72 Asset Management L.P. | 9,355,382 6.1% | 9,355,382 (New Position) | View |
| 2019-05-29 4:46 pm Purchase | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | INTEGRATED CORE STRATEGIES (US) LLC | 6,194,004 5.6% | 6,194,004 (New Position) | View |